Patient-reported outcomes in KEYNOTE-006, a randomised study of pembrolizumab versus ipilimumab in patients with advanced melanoma
Open Access
- 4 October 2017
- journal article
- research article
- Published by Elsevier BV in European Journal Of Cancer
- Vol. 86, 115-124
- https://doi.org/10.1016/j.ejca.2017.08.032
Abstract
No abstract availableKeywords
Funding Information
- Merck
This publication has 29 references indexed in Scilit:
- Clinical Implications of Co-Inhibitory Molecule Expression in the Tumor Microenvironment for DC Vaccination: A Game of Stop and GoFrontiers in Immunology, 2013
- Health related quality of life outcomes for unresectable stage III or IV melanoma patients receiving ipilimumab treatmentHealth and Quality of Life Outcomes, 2012
- Improved Survival with Ipilimumab in Patients with Metastatic MelanomaNew England Journal of Medicine, 2010
- The PD‐1 pathway in tolerance and autoimmunityImmunological Reviews, 2010
- Quality of life data as prognostic indicators of survival in cancer patients: an overview of the literature from 1982 to 2008Health and Quality of Life Outcomes, 2009
- PD‐1 signaling in primary T cellsImmunological Reviews, 2009
- Estimation of minimally important differences in EQ-5D utility and VAS scores in cancerHealth and Quality of Life Outcomes, 2007
- PD-1:PD-L inhibitory pathway affects both CD4+ and CD8+ T cells and is overcome by IL-2European Journal of Immunology, 2002
- The European Organization for Research and Treatment of Cancer QLQ-C30: A Quality-of-Life Instrument for Use in International Clinical Trials in OncologyJNCI Journal of the National Cancer Institute, 1993
- EuroQol - a new facility for the measurement of health-related quality of lifeHealth Policy, 1990